The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1312
Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Apriso (Salix) is a new formulation of mesalamine (5-aminosalicylic acid; 5-ASA) approved by the FDA for maintenance of remission in mild to moderate ulcerative colitis (UC). Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease. Various mesalamine formulations have been developed to target drug delivery to areas of the small intestine and colon. Most of these agents require frequent dosing and have a high pill burden. The newest products – Lialda, introduced in 2007,1 and now Apriso – can be dosed once daily.

PHARMACOLOGYApriso capsules have a pHdependent coating around a polymer matrix core that contains mesalamine granules. The outer coating dissolves at a pH ≥6, exposing the core to luminal fluid and releasing the drug into the distal ileum and colon. About 20-30% of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis
Article code: 1312b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian